Cited 58 times in
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2016-02-04T11:57:07Z | - |
dc.date.available | 2016-02-04T11:57:07Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0741-238X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141562 | - |
dc.description.abstract | INTRODUCTION: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV is affected by DCV resistance-associated polymorphisms (RAPs) in HCV NS5A. The prevalence and influence of these RAPs on 12-week sustained virologic response (SVR12) to DCV + ASV was evaluated in Asian and non-Asian patients. METHODS: Data were pooled from 5 national and international studies of patients with HCV genotype 1b (GT-1b) receiving DCV + ASV at their recommended doses. Baseline NS5A RAPs and their effect on SVR12 were assessed overall, in older (≥65 years) patients, patients with cirrhosis, and in patients stratified by baseline HCV RNA or prior treatment experience with interferon-based therapy. RESULTS: Baseline NS5A sequences were available from 988 patients (374 Japanese; 125 Korean/Taiwanese; 489 from non-Asian countries), 979 of whom were assessed for SVR12. Pretreatment NS5A-L31F/I/M/V and/or NS5A-Y93H polymorphisms were present in 18% of Japanese and 12-13% of non-Japanese patients; these RAPs reduced SVR12 by 54.9% overall (93.9% [787/838] SVR12 when absent, 39.0% [55/141] SVR12 when present), with comparable reductions observed in Asians and non-Asians and across all categories of treatment experience, age, and cirrhosis. RAP-associated SVR12 rates declined with increasing baseline HCV RNA (SVR12 with RAPs: 64.7% [11/17] at 5-6 log10 IU/mL, 29.8% [14/47] at 7-8 log10). Without baseline RAPs, very high SVR12 rates (92-100%) were observed in older patients and patients with cirrhosis irrespective of national origin, with similarly high rates observed among treatment-naïve and interferon-experienced patients and those with high baseline HCV RNA. CONCLUSIONS: Following DCV + ASV treatment, the SVR12 rates in GT-1b patients without baseline NS5A-L31F/I/M/V and/or NS5A-Y93H polymorphisms were very high (approximately 90-100%), irrespective of age, cirrhosis, prior interferon treatment, or baseline HCV RNA. FUNDING: Bristol-Myers Squibb. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 637~649 | - |
dc.relation.isPartOf | ADVANCES IN THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents/administration & dosage | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Drug Resistance, Viral/genetics | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepacivirus/genetics* | - |
dc.subject.MESH | Hepatitis C, Chronic/complications | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imidazoles/administration & dosage | - |
dc.subject.MESH | Imidazoles/therapeutic use* | - |
dc.subject.MESH | Isoquinolines/administration & dosage | - |
dc.subject.MESH | Isoquinolines/therapeutic use* | - |
dc.subject.MESH | Japan | - |
dc.subject.MESH | Liver Cirrhosis/drug therapy* | - |
dc.subject.MESH | Liver Cirrhosis/etiology | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Phosphoproteins/genetics | - |
dc.subject.MESH | Polymorphism, Genetic | - |
dc.subject.MESH | Sulfonamides/administration & dosage | - |
dc.subject.MESH | Sulfonamides/therapeutic use* | - |
dc.subject.MESH | Viral Nonstructural Proteins/genetics | - |
dc.subject.MESH | Young Adult | - |
dc.title | High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Fiona McPhee | - |
dc.contributor.googleauthor | Yoshiyuki Suzuki | - |
dc.contributor.googleauthor | Joji Toyota | - |
dc.contributor.googleauthor | Yoshiyasu Karino | - |
dc.contributor.googleauthor | Kasuaki Chayama | - |
dc.contributor.googleauthor | Yoshiiku Kawakami | - |
dc.contributor.googleauthor | Min Lung Yu | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Hiroki Ishikawa | - |
dc.contributor.googleauthor | Rafia Bhore | - |
dc.contributor.googleauthor | Nannan Zhou | - |
dc.contributor.googleauthor | Dennis Hernandez | - |
dc.contributor.googleauthor | Patricia Mendez | - |
dc.contributor.googleauthor | Hiromitsu Kumada | - |
dc.identifier.doi | 10.1007/s12325-015-0221-5 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J00048 | - |
dc.identifier.eissn | 1865-8652 | - |
dc.identifier.pmid | 26155891 | - |
dc.subject.keyword | Asunaprevir | - |
dc.subject.keyword | Daclatasvir | - |
dc.subject.keyword | Drug resistance | - |
dc.subject.keyword | Infectious diseases | - |
dc.subject.keyword | Viral hepatitis | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 32 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 637 | - |
dc.citation.endPage | 649 | - |
dc.identifier.bibliographicCitation | ADVANCES IN THERAPY, Vol.32(7) : 637-649, 2015 | - |
dc.identifier.rimsid | 30725 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.